Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Людмила РАЗБОРСКИfiledCriticalЛюдмила РАЗБОРСКИ
Priority to MDA20040128ApriorityCriticalpatent/MD2552G2/en
Publication of MD2552F1publicationCriticalpatent/MD2552F1/en
Publication of MD2552G2publicationCriticalpatent/MD2552G2/en
The invention refers to the pharmaceutical industry, in particular to the suppositories used for treatment of inflammatory processes in the rectum and urogenital system.Summary of the invention consists in that the medicament in the form of suppository contains phenolic compounds of propolis, oleic solution of vitamin E, glycerol, semisynthetic glycerides in the following component ratio, calculated for a suppository with the weight of 2,00 g:
MDA20040128A2004-05-192004-05-19Medicament in the form of suppository
MD2552G2
(en)
Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds.
Use of a composition comprising a compound derived from heterocycle to treat or prevent the loss of intestinal flow; composition comprising said compound; and kit that includes the composition.
Pharmaceutical combination comprising a purine derivative and a corticosteroid, beta-2 adrenoceptor agonist, antimuscarinic agent, among others; pharmaceutical composition; and its use to treat inflammatory or obstructive airway diseases.
Use of lactobacillus rhamnosus gg in combination with a long chain polyunsaturated fatty acid for the treatment, prevention or reduction of systemic inflammation in a formula-fed infant
methods for manufacturing a compound, for purifying a compound, for treating an individual having a neoplastic condition, having squamous cell carcinoma, and having basal cell carcinoma, for reducing or preventing the occurrence of a neoplastic condition in an individual, and for the reduction of serum triglycerides in an individual, compound, and, pharmaceutical composition